BIOLASE (NASDAQ:BIOL) released its earnings results on Wednesday. The medical technology company reported ($0.04) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.04), Bloomberg Earnings reports. The business had revenue of $12.63 million for the quarter. BIOLASE had a negative return on equity of 74.51% and a negative net margin of 36.28%.
BIOLASE (NASDAQ:BIOL) opened at $0.46 on Thursday. The stock has a market capitalization of $50.15, a P/E ratio of -1.48 and a beta of 1.81. BIOLASE has a twelve month low of $0.28 and a twelve month high of $1.45.
ILLEGAL ACTIVITY WARNING: “BIOLASE (BIOL) Releases Earnings Results, Hits Estimates” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/03/15/biolase-biol-releases-earnings-results-hits-estimates.html.
BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.